An assay for measuring hexosaminidase A in serum and leucocytes is described in which a centrifugal analyser is used for automation of the enzyme assays after manual heat inactivation. The assay was used in a screening programme to identify heterozygotes for Tay-Sachs disease in Ashkenazi Jewish subjects in the UK. The first results from this programme indicate a carrier frequency of 1 in 27. Automation of an assay for direct measurement of hexosaminidase A in serum using 4-methylumbelliferyl-,-N-acetylglucosamine-6-sulphate as substrate is also described. Comparison of data obtained from 66 control and 30 obligate carrier sera tested by this method and by heat inactivation showed improved discrimination using the sulphated substrate. Results obtained using the sulphated substrate for screening serum during pregnancy are also presented.
substrate, ganglioside GM2, is not degraded and accumulates in neuronal cells leading to the characteristic pathology of the disease.
Hex A is composed of a and I6 peptides. The other major isoenzymes, Hex B, Hex S, and the intermediate hexosaminidases, are composed of various combinations of a and Pi peptides. Mutation of the locus coding the , peptide causes reduction in the activity of all hexosaminidases except Hex S (which is composed ofa peptides only). The resulting condition, Sandhoff's disease (SHD), is biochemically distinguishable from TSD but clinically similar.
Carriers of the TSD gene have reduced Hex A activity,2 and are approximately 10 times more frequent in the Ashkenazi Jewish community than in the general population. This led to the introduction of screening programmes in the early 1970s to identify carriers. The method used for carrier testing in most laboratories involves determining the total Hex activity in serum, and the proportion of Hex activity which is heat labile under standardised conditions (predominantly Hex A) using the sensitive fluorogenic substrate 4-methylumbelliferyl-i-D-N-acetylglucosamine. The procedure can be automated using continuous flow equipment with two matched fluorimeters reading the product of the reaction of unheated and heated serum samples.4 A number of factors (pregnancy, inflammatory illnesses, oral contraceptive pill), which alter the proportion of Hex A relative to the other Hex isoenzymes in serum, can lead to false positive carrier identification.5 6 In these circumstances, assay of Hex A in leucocytes usually allows accurate classification of genotype.
Less empirical methods for assay of Hex A are based on use of 6-sulphated chromogenic7 or fluorogenic8 9 substrates. Hex A is considerably more active towards these substrates than is Hex B, and recent work indicates that use of the substrates has advantage in classification of Tay-Sachs disease genotypes, including carrier detection.7 9 The recognition of a splice junction defectl' and a four base insertion" in the Ashkenazi population, which together account for about 90% of the TSD Received for publication 19 Tay-Sachs camier screening protein/ml and diluted (1/10) in 0-75% human serum albumin in citrate-phosphate buffer, as above.
MANUAL HEXOSAMINIDASE ASSAY
The method was based on the heat inactivation procedure of Kaback,'5 the main difference being that inactivation was carried out for three hours at 50°C instead of two and three hours at 52°C, and the enzyme reaction was run for 60 minutes instead of 30 minutes. The reaction was stopped with 0-5 mol/l glycine-NaOH buffer, pH 10-3 (3 ml) and fluoresence read using a Perkin Elmer LS2B fluorimeter (366 rm filter, emission wavelength 448 nm).
AUTOMATED HEXOSAMINIDASE ASSAY FOR SERA AND LEUCOCYTES
In developing the automated assay for Hex A we attempted to reproduce as far as possible the conditions of our manual assay. The diluted sera or leucocyte sonicates were aliquoted into four analyser sample cups; two aliquots were heated at 50°C for three hours to inactivate Hex A while the other aliquots remained at 0°C in an ice bath. All four aliquots were then assayed using the centrifugal analyser with the parameters set as shown in the table, column A (substrate start mode; nonlinear chemistry). The concentration of the substratebuffer reagent was 3 75 mmol/l 4-methylumbelliferyl-P-D-N-acetylglucosamine (Sigma, St Louis) in 25 mmol/l Na2HPO4-15 mmol/l citric acid, pH 4-4. The stopping reagent was 0 5 mol/l glycine-NaOH, pH 10-3. Standard solutions of 4-methylumbelliferone (Koch-Light, Colnbrook) in water at the indicated concentrations (table) were used for daily calibration of the instrument. Time of incubation at 37°C was usually 10 minutes for both serum and leucocytes, but was increased to 20 minutes for low activity specimens. The Hex activity of the heat inactivated aliquots was compared with those kept on ice and the difference used to calculate the percentage Hex A for each sample. Known normal and heterozygote samples were assayed daily for quality control. and the incubation time was 20 minutes. Serum was diluted 1 in 10 with 12 mmol/l citrate-20 mmol/l phosphate buffer for these tests which enabled assays with sulphated and unsulphated substrates to be carred out with the same diluted samples.
Results

PRELIMINARY ASSESSMENT OF THE CENTRIFUGAL ANALYSER FOR HEX DETERMINATION
In developing the automated assay for hexosaminidase A the main change necessary was reduction of volume of stopping buffer from 3 ml in the manual assay to 75 W1. This was dictated by the pipetting procedure and rotor cuvette size of the centrifugal analyser. In order to assess the effectiveness of the smaller volume of buffer for stopping the enzyme reaction, the analyser was set to read the fluorescence of the product of the reaction of heated and unheated normal and heterozygous sera over a 10 minute period at 30 second intervals after addition of the glycine. Results showed that fluorescence slowly increased over this time by about 1% of the initial reading. It was concluded that during the 90 second reading period of the standard assay the increase would not be sufficient to introduce a significant error into the results.
The calibration of the analyser with different concentrations of 4-methylumbelliferone was found to be linear over the range studied (0-204 to 10-2 imol/l final concentration). The rate of reaction was found to be constant for 500 both normal serum (fig 1) and normal leucocyte extracts (fig 2) over the time studied (two to 20 minutes). Activity in normal leucocyte extracts was proportional to the protein concentration over the range 0-2 to 3-0 mg/ml, equivalent to 1 to 15 pg in the /0/ incubation mixture (fig 3) . 400
DIRECT (fig 7) . There was no clear discrimination if Hex A activity alone was considered. The same two control subjects who gave inconclusive results when tested by heat inactivation appeared near to the carrier group using the sulphated substrate (they are numbered as in fig 4) . SHD carriers were not readily identified using the sulphated substrate. It should be noted that the rate of hydrolysis of the sulphated substrate by Hex A is lower than the rate with the unsulphated substrate, and that units on the abscissae of figs 4 and 7 are therefore not directly comparable. . All subjects shown had been assigned carrier status using the leucocyte assay. The sulphated substrate gave clear discrimination between carriers and non-carriers, whereas there was overlap of the two groups when Hex A was measured by heat inactivation.
Discussion
The results presented here show that the heat inactivation method for determining Hex A in both sera and leucocytes is readily adaptable to a centrifugal analyser. Although not a completely automated procedure (the heat inactivation step is manual), the method has the advantage over a continuous flow system in not requiring dual fluorescence readings and careful balancing of instruments. Moreover, the ability to use the analyser to test leucocytes as well as . If a value outside these limits was obtained in any run, the data for that run were rejected and the 0 whole batch of specimens was reanalysed.
A study in which leucocytes and serum from normal subjects, TSD and Sandhoff's disease heterozygotes, and TSD patients were assayed simultaneously using our standard manual method and the automated method showed that the mean difference'6 between results was only 0-8 percentage points for analysis of leucocytes and 3-2 percentage points for serum. The automated method gave results for serum which were, on average, 3 2 percentage points higher than those given by the manual method, but the discrimination between normal, heterozygous, and TSD affected groups was not compromised. (fig 4) . This approach has been fetu5, a discussed by Gold,' who presented data for serum oinedpoint hexosaminidase as a two dimensional plot of Hex A versus Hex B. We found the approach to be useful in assessing genotype in borderline subjects (55 to 590/o particular Hex A in serum) before the leucocyte assay was the assay completed, but in practice always retested using ien plasma leucocytes. This involved recalling about 3% of er leads to subjects initially screened using serum. ing needle.
The carrier frequency found for the UK Ashkenazi Tay-Sachs population (1 in 27 based on 2965 subjects screened) i this fluid compares with that reported elsewhere (for example, advantage. 1 in 31 in a North American Jewish population').
which had
The assay for Hex A in serum using the sulphated unreliable substrate can also be readily automated. Measurement r tendency of Hex A activity alone was found to give poor ne protein discrimination between carriers and non-carriers, but leading to when plotted against Hex A as a fraction of total Hex mt that we (measured with the centrifugal analyser and the ntrols and unsulphated substrate) good discrimination was r reference obtained ( fig 7) . This assay has the advantage of y obtained. avoiding the heat inactivation step and may also detect escreening carriers of the rare TSD B1 variant who have normal processed Hex A activity when measured by the heat inactivation method.'8 19 A careful comparison of figs 4 and 7 assays, an shows that the two discriminant test with the sulphated -llet from a substrate gives better separation between carriers and terozygote normal subjects than the test based on heat inactivation. ,h batch of Bayleran et al8 also found this to be the case, using se samples manual assays and analysing their data to transform Hex A results obtained with the sulphated substrate to equivalent units to those obtained with the unsulphated substrate. However, these workers, and also Ben-Yoseph et al,9 obtained good separation between controls (37 and 33 studied in each series, respectively) and carriers (19 studied in both series) using serum Hex A activity as a single discriminant. In contrast, we found that with our larger groups of 66 controls and 30 carriers (and using slightly different assay conditions) poor separation of genotypes was obtained by measuring activity towards the sulphated substrate alone.
Screening of pregnant women poses particular problems since during pregnancy the serum activity of heat stable intermediate Hex isoenzymes increases, thus reducing the relative activity of Hex A and leading to a falsely low percentage Hex A.5 In an attempt to overcome this problem we assayed absolute activity of Hex A in serum from pregnant carriers and non-carriers using both the heat inactivation method and the sulphated substrate.
There was no discrimination between pregnant carriers and pregnant non-carriers when Hex A in serum samples was measured by heat inactivation ( fig  8) . However, discrimination was improved in the group of patients studied when Hex A was measured with the sulphated substrate (fig 9) . In using the heat inactivation method it is assumed that only Hex A is thermolabile, but other hexosaminidases may also be thermolabile to a small degree,20 and this will lead to errors in Hex A determination. On the other hand, measurement of Hex A activity with the sulphated substrate relies on its specificity for this substrate, and errors will be introduced if any hydrolysis by other isoenzymes occurs. On balance, since our studies (Fensom and Landels, unpublished data) show that Hex B and Hex I separated by FPLC have negligible activity towards the sulphated substrate, it is likely that the slight thermolability of other isoenzymes introduces more error than non-specific hydrolysis of the sulphated substrate, thus explaining the better discrimination obtained with the sulphated substrate.
In addition to problems caused during pregnancy by an increase in Hex I, a further complication arises from increase in Hex A itself. This increase is probably the result of transfer of fetal Hex A to the mother. Navon et a12' showed that serum Hex A remained unchanged during the second trimester in three pregnant obligate carriers for TSD who carried affected fetuses, whereas it increased four-fold in two pregnant mothers affected with adult onset GM2-gangliosidosis who carried unaffected fetuses. This complication is likely to reduce the usefulness of measurement of Hex A in serum with the sulphated substrate for carrier detection at later gestational times; however, our results in sera taken earlier during pregnancy are encouraging (fig 9) . In the case of one obligate carrier, serum was sampled during two pregnancies, one where the fetus was affected with TSD, and the other where the fetus was a non-carrier. Both sera were taken at 10 weeks' gestation; the Hex A levels are very similar (see fig 7; the two points are joined). Thus, at 10 weeks' gestation, the fetal contribution to maternal serum of Hex A appears to be very small, and even when the fetus is a non-carrier should not cause the maternal serum Hex A level of carriers to approach the non-carrier range. These results, though encouraging, are preliminary; at any gestation it remains prudent to confirm carrier status with the more reliable leucocyte assay.
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